Tryozi Review: What Its GLP-1 Documents Establish—and What They Don’t

A medication study and a telehealth company’s website answer different questions. That distinction matters at Tryozi, which advertises compounded semaglutide injections for $79 a month and compounded tirzepatide injections for $129 a month. Those are concrete commercial offers, not evidence that the company’s preparations produce a particular outcome. Tryozi itself acknowledges that compounded versions have not been studied separately. The useful question is therefore not simply whether the ingredient names are familiar, but what is documented about the actual product, clinical process and ongoing service.

This review examines Tryozi’s public documentation consulted October 19, 2026. The platform identifies its operator, clinical partner, pharmacy network, advertised prices and patient contact routes. That is a meaningful documentary foundation. However, its homepage and policies differ on membership, the timing of the first charge, included services and refunds. For adults considering the service, those differences deserve clarification before enrollment—not because they establish poor medical care, but because clear commercial terms and clear clinical responsibilities are separate, necessary parts of evaluating an offer.

At a glance

Platform and clinical responsibility: Tryozi Group LLC operates the platform; its terms assign clinical care, prescribing and fulfillment to clinicians and pharmacies through OpenLoop Health and affiliated medical groups.
Sources: [5] [9]
Advertised compounded injections: Semaglutide is advertised at $79 monthly and tirzepatide at $129 monthly, each described as a lifetime deal prepared by a licensed U.S. 503A pharmacy.
Sources: [7]
Evidence boundary: Tryozi says compounded medications are not FDA approved and that compounded versions have not been studied separately.
Sources: [7]
First charge: The homepage advertises a free, no-obligation clinical review, while the subscription policy says the first month is charged when the intake form is completed.
Sources: [7] [10]
Cancellation deadline: The subscription policy requires cancellation requests to be received at least 72 hours before billing; missing that deadline triggers another cycle’s charge.
Sources: [10]

Start with the product evidence, not the advertised result

Tryozi makes two useful disclosures: compounded medications are not FDA approved, and compounded versions have not been studied separately. Those statements limit what readers can reasonably infer from research involving other products. FDA explains that compounded preparations do not undergo its premarket review for safety, effectiveness and quality. Nonapproval alone does not prove clinical inequivalence, but neither does a familiar ingredient name establish that a particular preparation has the evidence supporting an approved product.

FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Tryozi describes its compounded injections as prepared by licensed U.S. 503A pharmacies. That is a provider statement, not an independent verification of a particular pharmacy’s licensing or a particular prescription’s suitability. FDA approval applies to a specific product; it is not an endorsement of the platform arranging access to it.

The consulted documentation does not establish measured outcomes for Tryozi patients. Studies of semaglutide or tirzepatide cannot fill that gap by themselves, and this review does not assign the platform an efficacy ranking. Our guide to why a clinical trial is not a telehealth company performance report explains the distinction. The practical next step is to identify the exact preparation being offered and the clinician’s reason for selecting it, rather than treating general medication research as a Tryozi performance guarantee.

Sources: [7] [1] [3] [4]

Who is responsible for the service?

Tryozi identifies its operator as Tryozi Group LLC, with a published address at 21113 Johnson St, Suite 101, Pembroke Pines, Florida 33029. It describes itself as a patient management platform working with independent physicians and practitioners, rather than directly providing medical or pharmacy services. Its disclaimer also says payment does not guarantee that a prescription will be written or dispensed. That distinction matters when deciding whom to contact about a clinical decision versus a billing problem.

The terms attribute clinical care, prescribing and fulfillment to licensed clinicians and pharmacies through OpenLoop Health, Inc. and its affiliated medical groups. OpenLoop coordinates partner pharmacies, and prescriptions may move between those pharmacies for fulfillment reasons. The named partners are RedRock Pharmacy, Health Warehouse, Precision Medicine and Triad Rx. Naming them improves transparency, but does not establish which will fill an individual prescription or whether each named pharmacy prepares the compounded products advertised.

Tryozi says it currently offers services across all 50 states and Washington, D.C., while expressly warning that some services may not be available in every jurisdiction and that availability can change. A nationwide platform claim therefore is not confirmation that every advertised medicine is available at a particular address. Before paying, readers should request the responsible medical group and likely dispensing pharmacy for their state. The consulted material does not independently verify professional licenses or pharmacy authorizations.

Sources: [5] [9]

Four advertised options, with different evidence questions

Tryozi’s homepage displays two compounded injectable options and two brand-name prescription options. The compounded semaglutide card shows $79 per month against an original $279; tirzepatide shows $129 against $379. The site labels both compounded offers a lifetime deal with monthly billing. It also advertises the same price at every dose. These are commercial representations, not complete explanations of continued eligibility for the offer after cancellation, a treatment interruption or re-enrollment.

The brand-name cards list Ozempic at $1,299 monthly and Zepbound at $1,399 monthly. Tryozi identifies them as semaglutide from Novo Nordisk and tirzepatide from Eli Lilly, respectively, and warns that availability and coverage may vary. The consulted pages do not establish accepted insurers, guaranteed coverage or a prior-authorization service. Listing FSA/HSA among payment methods does not establish insurance acceptance or determine whether a particular expense qualifies under a reader’s account.

The table preserves the advertised product distinctions without treating the options as interchangeable. A more detailed discussion of approved medicines and compounded preparations explains why product identity matters. Separately, the homepage’s offer countdown discloses that it repeats every seven hours and 51 minutes. Readers should not interpret that repeating clock as evidence of a unique, one-time expiration deadline or use it in place of reviewing the actual enrollment terms.

Tryozi’s advertised options; the subscription and inclusion qualifications discussed below still matter.
Advertised option	Displayed price and interval	Documented qualification
Compounded semaglutide injection	$79 monthly; original price shown as $279	Lifetime deal; monthly billing; prepared by a pharmacy described as a licensed U.S. 503A pharmacy
Compounded tirzepatide injection	$129 monthly; original price shown as $379	Lifetime deal; monthly billing; same-price-at-every-dose claim
Ozempic, brand-name semaglutide	$1,299, billed monthly	Availability and coverage may vary
Zepbound, brand-name tirzepatide	$1,399, billed monthly	Availability and coverage may vary

Sources: [7] [5] [1]

What the online evaluation does—and does not—establish

The advertised entry point is a two-minute questionnaire offering a personalized estimate and treatment options. The homepage describes questions about health and goals, completed online without a clinic visit, followed by review by a licensed U.S. clinician in one to two days. It calls that review free and without obligation. Neither a questionnaire result nor an estimate is final clinical approval, and the platform’s own disclaimer makes clear that payment does not guarantee a prescription.

Tryozi publishes general criteria of BMI at least 27, or at least 25 with a related condition, and ages 18–74 for new patients. These are the provider’s stated screening criteria, not individualized eligibility advice. They also differ from the general adult pharmacotherapy thresholds described by NIDDK: BMI at least 30, or at least 27 with weight-related health problems. Neither set of thresholds replaces review of the particular medication, medical history and circumstances by a treating clinician.

The site asks patients to disclose pregnancy, breastfeeding, medications and medical conditions, leaving appropriateness to the clinician. However, the consulted pages do not define whether the consultation is a video appointment, an asynchronous exchange or another format. They also do not reconcile the free-review claim with a policy that starts charges at intake completion. Readers should identify the precise payment-authorization step before submitting the form, rather than assuming the advertised review window guarantees a charge-free evaluation.

Sources: [7] [6] [9] [10] [2]

Included care is advertised broadly but defined less precisely

Tryozi’s homepage says every plan includes licensed-clinician consultations, standard base labs through Quest or Labcorp, medication, discreet home shipping and 24/7 patient support from a real person. It also promises ongoing check-ins and care-team access. These are meaningful advertised components: they describe more than a medication checkout. But the subscription policy qualifies the package by saying the services, labs and medications covered by the single subscription price may vary.

That qualification leaves practical questions unanswered. The consulted documentation does not specify which laboratory tests constitute base labs, when they are repeated or what circumstances could generate extra charges. It also does not establish a check-in frequency, a guaranteed response time or the professional credentials of every person available through support. Around-the-clock access to a care team should not be read as a promise that a prescribing clinician will respond immediately to every message.

NIDDK describes follow-up as attention to response and tolerance, not merely continued payments. That provides a useful standard for questions, rather than evidence about Tryozi’s actual performance. Ask who reviews progress, how concerns reach the prescriber and what happens when treatment needs reassessment. Our guide to clinical follow-up beyond renewal notices develops those questions. Tryozi’s public promises establish that follow-up is advertised; they do not establish its detailed schedule or measured quality.

Sources: [7] [10] [2]

Shipping claims stop short of a delivery protocol

The homepage places receiving medication at “about a week,” conditional on approval, and says the prescription ships to the patient’s door. That is an approximate advertising timeline, not a clearly separated schedule for clinical review, pharmacy preparation, dispatch and arrival. The consulted documentation does not specify the carrier, transit time, package tracking, cold-chain procedure or terms for a lost or delayed shipment. A shipment promise should not be converted into a guaranteed arrival date.

The pharmacy network creates another handoff to clarify. OpenLoop coordinates fulfillment, and prescriptions may transfer among partner pharmacies. A patient therefore needs the actual dispensing pharmacy’s name and contact information, not just the platform’s general support details. The cancellation policy says damaged items may be replaced after evidence of damage is received, while incorrect medications will be replaced by the pharmacy. Those provisions address particular problems; they do not amount to a comprehensive delivery guarantee.

FDA explicitly advises not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy to resolve the concern. That advice is general regulatory guidance, not a finding about Tryozi shipments. FDA also reports medication-measurement and administration errors involving compounded products, some associated with hospitalization. Patients should clarify instructions with the prescriber or pharmacist rather than infer how to use a product from a review, price card or another person’s prescription.

Sources: [7] [5] [10] [1]

Billing and cancellation need a written reconciliation

The homepage advertises “no membership” and cancellation at any time, but the policies describe membership in an automatically renewing subscription. The subscription begins, with the first month charged, when the intake form is completed. Separately, the homepage says multi-week plans are charged in full upfront and medication then ships every four weeks. It does not clearly identify which displayed monthly offers fall under that provision. Four-week shipments are not the same interval as calendar-month billing.

The terms authorize selected-service charges plus applicable taxes. Accepted payment methods are Visa, Mastercard, FSA/HSA, Apple Pay and Google Pay; American Express is not accepted. Cancellation can be requested through customer service or an online-account process, if available. The request must be received at least 72 hours before billing. Otherwise, the next cycle is charged and cancellation takes effect on the subsequent billing date. Services remain available through the end of the applicable cycle; cancellation does not itself create a refund.

Refund wording is inconsistent. One passage promises a full refund for medical disqualification; another limits it to remaining charges after disqualification. Elsewhere, the policy says a refund may be issued and limits approved refunds to the most recent billing cycle, excluding earlier cycles. Other cancellations are expressly nonrefundable. The prudent documentary question is specific: what amount would be returned if the initial clinician declines treatment, and which clause governs? The public wording does not support one unqualified refund promise.

Sources: [7] [5] [10]

Contact routes, records and remaining documentation gaps

Tryozi publishes support@tryozi.com and (336) 365-0623 for questions. Those are useful routes for requesting the exact plan terms, pharmacy assignment and cancellation confirmation. The privacy notice describes rights to obtain medical records, request corrections and confidential communications, seek limits on sharing and file complaints without retaliation. The pages reviewed are in English; they do not establish Spanish-language care or clinical documentation. Readers who need another language should confirm that capability rather than infer it from online availability.

The privacy policy says advertising and analytics technologies are kept off intake, quiz, account and checkout pages. The terms also require separate consent for text-message programs: accepting the terms does not enroll someone, and promotional-text consent is not a condition of purchase. These are documented policy commitments, not the results of an independent technical privacy audit. A California notice also mentions issuing policies and offering financial or insurance products, without explaining how that language relates to the GLP-1 service.

That unrelated language is a reason to request clarification, not evidence of a legal violation. More broadly, public documentation can establish what Tryozi promises and how it allocates responsibilities, but cannot verify every implementation detail. Our guide to what provider documents can prove explains that limit. Here, unresolved issues include the precise pharmacy assignment, included lab schedule, consultation format, lifetime-offer continuity and actual first-charge sequence. Written answers would make the offering easier to evaluate without substituting marketing confidence for evidence.

Sources: [6] [8] [5] [9]

Questions & answers

Is Tryozi itself the medical provider or pharmacy?

No. Tryozi describes itself as a patient management platform and says it does not directly provide medical or pharmacy services. Its terms place clinical care, prescribing and fulfillment with clinicians and pharmacies through OpenLoop Health and affiliated medical groups. Ask for the specific treating entity and dispensing pharmacy assigned to your care.

Sources: [9] [5]

Are the $79 and $129 prices introductory offers?

The homepage describes the compounded semaglutide injection at $79 monthly and compounded tirzepatide injection at $129 monthly as lifetime deals, not explicitly as first-month-only prices. However, the consulted documents do not define how the deal survives cancellation, interruption or re-enrollment. They also do not clearly reconcile monthly cards with the separate upfront-payment clause for multi-week plans.

Sources: [7]

Will completing the quiz trigger a charge?

The entry page describes a questionnaire for an estimate and treatment options. The subscription policy says charging begins when the intake form is completed, while the homepage advertises a free, no-obligation clinical review. The documents do not establish exactly how those steps connect. Confirm which submission authorizes payment and whether clinical review occurs before that authorization.

Sources: [6] [10] [7]

Are labs and clinician consultations definitely included?

The homepage says licensed-clinician consultations and standard base labs through Quest or Labcorp are included in every plan. The subscription policy says covered services, labs and medications may vary. Request an itemized description for the selected plan, including the actual tests, repeat-testing arrangements and any circumstances that could create additional charges. The consulted pages do not resolve those details.

Sources: [7] [10]

How do I stop renewal, and does that mean a refund?

Request cancellation through customer service or the account process, if available, with receipt at least 72 hours before billing. Missing that deadline means another cycle is charged. Cancellation is not a general refund entitlement: the policy excludes refunds for ordinary cancellations and uses differing language for medical-disqualification refunds. Ask for written confirmation of the effective cancellation date and any approved refund amount.

Sources: [10]

Does medication research establish results for Tryozi’s compounded injections?

No. Tryozi acknowledges that compounded versions have not been studied separately. Research on studied semaglutide and tirzepatide products does not establish outcomes for this platform, its compounded preparations or an individual patient. That limitation is not proof that a preparation is clinically inequivalent. It means product identity and the prescribing rationale require their own assessment rather than borrowing a trial’s headline result.

Sources: [7] [1] [3] [4]

Our assessment

Tryozi provides a recognizable service outline: an identified operator, a named clinical partner, named pharmacy partners, published medication prices and accessible support contacts. Its explicit acknowledgment that compounded products lack FDA approval and have not been studied separately is important. Those disclosures support a more careful reading than treating medication research as proof of company performance. The principal weakness is documentary consistency. Free review versus intake charging, no-membership advertising versus subscription renewal, universal inclusions versus variable coverage, and conflicting refund language leave material questions unresolved. Before enrolling, obtain written confirmation of the exact product and pharmacy, first charge, billing interval, included labs and follow-up, cancellation deadline and medical-disqualification refund. Clear answers would improve decision readiness; they would still not establish individualized suitability or guarantee treatment outcomes.

Visit Tryozi’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Tryozi Review: What Its GLP-1 Documents Establish—and What They Don’t

At a glance

01Start with the product evidence, not the advertised result

02Who is responsible for the service?

03Four advertised options, with different evidence questions

04What the online evaluation does—and does not—establish

05Included care is advertised broadly but defined less precisely

06Shipping claims stop short of a delivery protocol

07Billing and cancellation need a written reconciliation

08Contact routes, records and remaining documentation gaps